Senescent osteocytes act as endocrine negotiators that couple bone remodeling to systemic metabolism through SASP‑derived microRNA‑21
Hypothesis
Senescent osteocytes secrete a specific SASP component—microRNA‑21 packaged in extracellular vesicles—that travels via circulation to metabolic tissues (liver, adipose, pancreas) and modulates insulin signaling. When senescence is transient, this signal fine‑tunes glucose homeostasis; when senescent osteocytes accumulate chronically, sustained miR‑21 export drives insulin resistance. Thus, senescent osteocytes function as negotiators balancing skeletal repair with whole‑body metabolic state.
Mechanistic Rationale
- Senescent cells deploy a regulated SASP that includes cytokines, chemokines, growth factors and non‑coding RNAs (Mechanisms and functions of cellular senescence).
- Osteocytes, as the most abundant bone cell, reside in lacuno‑canalicular networks and can release extracellular vesicles that carry microRNAs to distant organs (Cellular senescence and inter‑organ communication).
- microRNA‑21 is known to target PTEN and SOCS1, pathways that attenuate insulin receptor signaling; its extracellular circulation has been linked to metabolic dysfunction in other contexts.
- The SASP regulators NF‑κB/C/EBPβ and cGAS‑STING drive selective loading of miR‑21 into vesicles, providing a mechanism for coordinated output (Unbiased analysis of SASP).
- In acute settings, transient osteocyte senescence (e.g., after micro‑fracture) would produce a limited miR‑21 pulse that transiently suppresses PTEN in hepatocytes, enhancing insulin sensitivity to support repair; chronic senescence yields constant high miR‑21, leading to sustained PTEN suppression, feedback inhibition of insulin signaling, and insulin resistance.
Testable Predictions
- Aged mice with increased p16^INK4a^‑positive osteocytes will show elevated circulating osteocyte‑derived EVs containing miR‑21 and concomitant glucose intolerance.
- Genetic clearance of senescent osteocytes (using p16‑3MR or INK‑ATTAC) will reduce EV‑miR‑21 levels and improve glucose tolerance, but will also impair callus formation after tibial fracture due to loss of the transient SASP burst.
- Administration of synthetic miR‑21‑laden EVs isolated from young, transiently senescent osteocyte cultures will rescue the glucose intolerance of senescent‑osteocyte‑cleared mice without affecting bone mass.
- In vitro, exposing primary osteocytes to irradiation‑induced senescence will increase NF‑κB activity, elevate miR‑21 loading into EVs, and these EVs will decrease PTEN expression in hepatocytes and reduce insulin‑stimulated AKT phosphorylation.
Potential Experimental Approaches
- In vivo lineage tracing: Cross Dmp1‑CreERT2 with Rosa26‑LSL‑tdTomato and p16‑3MR to label osteocytes, induce senescence with low‑dose irradiation, track EV miR‑21 by RT‑qPCR from plasma.
- Metabolic phenotyping: Perform glucose tolerance tests and insulin tolerance tests before and after senolytic treatment (navitoclax or dasatinib+quercetin) in aged mice.
- EV isolation and characterization: Use ultracentrifugation or size‑exclusion chromatography to collect plasma EVs, assay miR‑21 content, and perform functional transfer assays to HepG2 cells.
- Rescue experiments: Inject miR‑21‑rich EVs from senescent osteocyte cultures into senolytic‑treated mice and monitor metabolic readouts.
- Controls: Use EVs from non‑senescent osteocytes or from osteocytes transfected with miR‑21 antagonist to verify specificity.
If the predictions hold, the data would support the idea that senescent osteocytes are not merely deleterious remnants but active negotiators that secrete a defined SASP metabolite (miR‑21) to regulate systemic insulin sensitivity, linking bone health to metabolic homeostasis. Conversely, failure to observe changes in circulating miR‑21 or metabolic phenotypes upon osteocyte‑specific senolysis would falsify the hypothesis.